Thèses sur le sujet « Antigeni tumore associati »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les 50 meilleures thèses pour votre recherche sur le sujet « Antigeni tumore associati ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Parcourez les thèses sur diverses disciplines et organisez correctement votre bibliographie.
DI, CRISTANZIANO VERONICA. « Caratterizzazione e valutazione del ruolo immunologico di un nuovo antigene associato all'adenocarcinoma del colon-retto : colorectal tumor-associated antigen 1 (COA-1) ». Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2008. http://hdl.handle.net/2108/432.
Texte intégralRecently, a new colorectal cancer (CRC)-associated antigen, denominated colorectal tumorassociated antigen-1 (COA-1), recognized by CD4+ T lymphocytes in a HLA class IIrestricted way and encoded by UBXD5 gene, was identified. In this study, we evaluated whether COA-1 can evoke a specific T cell-mediated response in CRC patients and whether this antigen can represent a tool to design new protocols of immunotherapy and a marker for the progression of the disease. Peripheral blood lymphocytes isolated from CRC patients have been in vitro stimulated with the immunogenic epitope of COA-1441-460 (FSTFPPTLYQDDTLTLQAAG) and the antigen- and tumor immunological response was analyzed by IFN-g ELISPOT assay. We could isolate COA-1 specific and tumor reactive T lymphocytes from all (n= 7) HLADRb1* 0402+ or *1301+ CRC patients with progressive disease (Dukes’ C and D), but not in patients (n= 4) with early stage tumor (Dukes’ A and B). Furthermore, these T lymphocytes had a CD3+CD4+CD69+CD45RA+ phenotype, compatible with the activated effector-type T cell subset, and most of them exerted cytotoxic activity against tumor cells expressing COA-1 and the specific MHC restriction elements. In addition, we have verified whether COA-1 specific reactivity could be isolated from PBMCs of CRC patients by the usage of autologous dendritic cells loaded with tumor lysate. Tumor reactive and COA-1 specific CD4+ T cells colud be isolated by in vitro stimulation of PBMCs either with intact tumor cells and with DC pulsed with tumor lysate, suggesting that this antigen can generate a dominant immunological response against CRC. In conclusion, the results of this study indicate that COA-1 can be a relevant antigen for the anti-tumor immune response in CRC patients, correlating with the progression of the disease, and suggest that this molecule is suitable for immunotherapeutic protocols of these patients.
Nastke, Maria-Dorothea. « T-cell epitopes from viral and tumor associated antigens induction and analysis of antigen-specific T cells / ». [S.l. : s.n.], 2005. http://www.bsz-bw.de/cgi-bin/xvms.cgi?SWB12168223.
Texte intégralLotz, Carina. « Tolerance and immunity to human tumor-associated antigens ». [S.l.] : [s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=970660308.
Texte intégralSheu, Fong-Shyong. « Characterizations of a tumor-associated antigen COX-1 ». Thesis, University of British Columbia, 1991. http://hdl.handle.net/2429/30332.
Texte intégralMedicine, Faculty of
Obstetrics and Gynaecology, Department of
Graduate
Ullenhag, Gustav. « Vaccine Therapy of Colorectal Cancer Patients with Tumor Associated Antigens ». Doctoral thesis, Uppsala University, Oncology, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3399.
Texte intégralIn this thesis, two different vaccines were evaluated as adjuvant therapy for patients with colorectal cancer. The ability of the two candidate vaccines to generate antigen-specific cellular and humoral responses, respectively, was studied. The effectiveness of granulocyte colony stimulating factor (GM-CSF) as a cytokine adjuvant to augment the immune response was also examined.
The first vaccination strategy involved immunization with the recombinant tumor-associated protein, carcinoembryonic antigen (CEA). Recombinant CEA was administered at 4 different dose levels 7 times during one year. Peripheral blood samples were regularly analyzed during 36 months. This vaccination regimen induced a strong immunoglobulin 1 (IgG1) and IgG4 response, a moderate IgG2 response and a weak IgG3 response against CEA. GM-CSF markedly augmented the effect on IgG1 and IgG4 as well as the T cell response. In contrast, dose of rCEA had no or modest effect on induced immune responses. The response gradually increased during the 12 months immunization period. Responses of all three IgG subclasses and of T cells were protracted up to 36 months. The anti-CEA IgG titers related significantly to survival. Functional HLA-DR epitopes of CEA could be defined. These major histocompatibility class II epitopes may serve as putative components of a peptide-based vaccination strategy.
The other vaccine strategy consisted of the tumor-associated antigen epithelial cell adhesion molecule (Ep-Cam) expressed as a transgene in a viral vector, ALVAC. Patients were immunized subcutaneously/intradermally 3 times over 6 weeks and monitored for immune responses for 46 weeks. No anti-Ep-Cam specific humoral response was induced, but Ep-Cam specific type 1 T cells (interpheron-gamma production) were induced, mainly in the GM-CSF group. The cytotoxic cellular response appeared late, or a few months after the last immunization.
Both vaccines were well tolerated. Since GM-CSF was an important component for both regimens, immungenicity of this cytokine was assessed. Multiple immunizations with low dose GM-CSF were associated with a low incidence of GM-CSF antibodies that did not neutralize the biological effect of GM-CSF.
In conclusion, both vaccines are promising candidate vaccines. GM-CSF is necessary to induce a strong humoral and cellular immune response. Large clinical trials are urgently warranted to evaluate the clinical efficacy.
Hishizawa, Masakatsu. « Identification of tumor-associated antigens in hematological malignancies by SEREX ». Kyoto University, 2006. http://hdl.handle.net/2433/143835.
Texte intégralShi, Mengchao. « Design and Synthesis of a Novel Entirely Carbohydrate-Based Conjugate for Cancer Vaccine Development ». University of Toledo / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1470412718.
Texte intégralDullforce, Per. « Cytotoxicity mediated by monoclonal antibodies to tumour associated antigens ». Thesis, University of Nottingham, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.293660.
Texte intégralRuiz, Elena. « DNA fusion vaccines against HPV16 E7 antigen-associated cancers ». Thesis, University of Southampton, 2011. https://eprints.soton.ac.uk/374745/.
Texte intégralSchecter, Robyn Lee. « A double determinant serum assay for detecting breast tumor associated antigen / ». Thesis, McGill University, 1987. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=66270.
Texte intégralMiddleton, Catrin Heledd. « Recombinant tumor-associated antigen production and autoantibody detection in hepatocellular carcinoma ». Thesis, University of Nottingham, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.595679.
Texte intégralAl-Qudaihi, Ghofran. « Studies on the immunogenicity of tumour associated antigens in leukaemia ». Thesis, University of Newcastle Upon Tyne, 2011. http://hdl.handle.net/10443/1254.
Texte intégralLi, Li. « Purification and characterization of tumour associated antigens 340 and 791Tgp72 ». Thesis, University of Nottingham, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.301694.
Texte intégralDede, A. Y. « The identification of prostate cancer associated tumour antigens and biomarkers ». Thesis, Nottingham Trent University, 2015. http://irep.ntu.ac.uk/id/eprint/27929/.
Texte intégralLooi, Kok Sun. « Using proteomic approach to identify tumor-associated antigens as biomarkers in hepatocellular carcinoma ». To access this resource online via ProQuest Dissertations and Theses @ UTEP, 2008. http://0-proquest.umi.com.lib.utep.edu/login?COPT=REJTPTU0YmImSU5UPTAmVkVSPTI=&clientId=2515.
Texte intégralNastke, Maria-Dorothea [Verfasser], et Hans-Georg [Akademischer Betreuer] Rammensee. « T-cell epitopes from viral and tumor associated antigens : induction and analysis of antigen-specific T cells / Maria-Dorothea Nastke ; Betreuer : Hans-Georg Rammensee ». Tübingen : Universitätsbibliothek Tübingen, 2005. http://d-nb.info/1162199148/34.
Texte intégralAlmeida, Andreia Filipa Ferreira de. « Detection of tumor-associated sialylated O-glycans by MALDI-TOF/TOF ». Master's thesis, Universidade de Aveiro, 2012. http://hdl.handle.net/10773/10673.
Texte intégralUma das alterações fenótipicas mais comuns nos tumores são modificações no padrão de O-glicosilação na superfície da célula e nas glicoproteínas secretadas. Como consequência têm implicações nas suas funções biológicas. Em particular, tem sido descrito que algumas células tumorais sobreexpressam ou expressam de novo antigénios associados ao antigénio Thomsen-Friedenreich (TF), ou seja, sialil-Tn, sialil-T e disialyl-T. Estes epítopos resultam da paragem prematura do processo de O-glicosilação em proteínas e têm um impacto direto sobre a biologia do tumor. Assim sendo, a identificação destas modificações póstranslacionais anormais em proteínas é essencial para determinar as relações estrutura-função e descobrir novos alvos terapêuticos. Além disso, as proteínas que transportam estas alterações podem ser secretadas na corrente sanguínea, urina, e em outros fluidos corporais e, portanto, são explorados como biomarcadores em testes não invasivos. Atualmente a detecção de antigénios associados ao antigénio TF é baseado em métodos imunohistoquímicos em que, embora úteis para uma investigação de rotina, não conseguem descrever totalmente o padrão de glicosilação de uma dada proteína. Sendo assim, neste trabalho apresentamos uma abordagem analítica para determinar estes glicanos em quantidades minimas de glicoproteínas (picomole) isoladas a partir de géis SDS-PAGE. Resumidamente, as glicoproteínas são de-Oglicosiladas no gel por beta-eliminação redutiva, permetiladas e analisadas por nanoLC-MALDI-TOF/TOF. De seguida, os dados provenientes são sujeitos a uma seleção melhorada dos sinais analíticos relevantes, utilizando ferramentas de bioinformática. Esta abordagem foi, em seguida, aplicada com sucesso na validação do western blotting quanto à expressão de sialil-Tn numa glicoproteína isolada a partir da urina de ratos com tumores na bexiga induzidos quimicamente e no plasminogénio isolado a partir do soro de pacientes com lesões precursoras do cancro gástrico.
A common phenotypic change in tumors comprises alterations in the O-glycosylation of cell-surface and secreted glycoproteins with implications in their biological functions. In particular, it has been described that some tumor cells overexpress or de novo express Thomsen-Friedenreich (TF)-related antigens, namely sialyl-Tn, sialyl-T and disialyl-T. These epitopes result from a premature stop in protein Oglycosylation and have direct impact on tumor biology. As a result, the identification of these abnormal post-translational modifications of proteins is essential to determine structure-function relationships and designs novel therapeutics. Moreover, the proteins carrying these alterations can ultimately be shed into the blood stream, urine and other body fluids and thus be explored as biomarkers in non invasive tests. Currently the detection of TF-related antigens relies on immuno-based methods that, even though useful in a routine basis, often fail to fully highlight the glycosylation pattern of a given protein. Herein, we have systematized a target-driven analytical approach to determine these glycans in minute amounts of glycoproteins (picomole) isolated from SDS-PAGE gels. Briefly, the glycoproteins are to be de-O-glycosylated in-gel by reductive beta-elimination, permethylated and analyzed by nanoLC-MALDI-TOF/TOF with enhanced selection of the relevant analytical signals using bioinformatics tools. This approach was then successfully applied to validate western blotting assignments regarding the expression of sialyl-Tn in a glycoprotein isolated from the urine of rats with chemically-induced bladder tumors and in plasminogen isolated from the serum of patients with gastric cancer precursor lesions.
Ghidouche, Abderrezak. « Nectine-4 : nouvelle cible dans l'immunothérapie du cancer du sein ». Thesis, Aix-Marseille 2, 2011. http://www.theses.fr/2011AIX20677.
Texte intégralNectin-4 is a cell surface adhesion molecule, member of the Ig-superfamily, and is localized at adherens junctions. Nectin4 is expressed during embryogenesis but not in adult tissues, except in the skin. Mutations in nectin-4 gene in humans cause the EDSS syndrome that affects skin development (EctoDermal and Syndactly Syndrome). We and others have recently demonstrated that nectin-4 expression was a tumoral marker of breast, lung and ovarian carcinoma. We thus started to investigate the functional role of nectin-4 overexpression in breast cancer. Using in vitro and in vivo assays, the preliminary results demonstrate that nectin-4 increased the tumorigenicity of malignant cells.Altogether, these results suggest that nectin-4 might be a candidate target forimmunotherapy (vaccination and antibody based therapy). Using a multiplex approachbased on biochemical, cellular and algorithmic assays, five relevant nectin-4 epitopes were identified. Specific cytotoxic T lymphocyte (CTL) populations from healthy donors that recognized and lyzed peptide-pulsed HLA-A*0201 tumor cells were identified. HLAA*0201-restricted CTL that recognized the N4-145 (VLVPPLPSL) nectin-4 epitope was characterized extensively. This CTL kills breast tumor cells that express nectin4, strongly demonstrating that this peptide could be naturally processed and recognized by specific CTL. In parallel, we also tested a blocking monoclonal antibody against the extracellular region of nectin-4. We next demonstrated that this antibody reduced the metastatic capacity of tumors expressing nectin4. To summarize, in this study, we identified nectin-4 as a newcell surface Tumor Associated Antigen and demonstrated its likely implication in cancertumorigenesis. In parallel, we have developed the specific tools required to conduct an effective immunotherapy targeting nectin4 over-expressing cells, which are currently under investigation
Mathew, John. « Spectrum of autoantibody response to tumour associated antigens in normal population ». Thesis, University of Nottingham, 2013. http://eprints.nottingham.ac.uk/56070/.
Texte intégralMosolits, Szilvia. « Natural and induced immunity aginst the tumour-associated antigen, Ep-CAM / ». Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-752-5.
Texte intégralKremling, Heidi. « Expression and function of the tumor associated antigen EpCAM in early esophageal carcinoma ». Diss., Ludwig-Maximilians-Universität München, 2014. http://nbn-resolving.de/urn:nbn:de:bvb:19-182881.
Texte intégralRojas, JoseÌ-Manuel. « Identification of novel immunogenic HLA-DR-restricted peptides from tumour-associated antigens ». Thesis, Nottingham Trent University, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273771.
Texte intégralMcCurry, Dustin. « Tumor Associated Antigens Harbor Readily Defined and Universally Immunogenic Regions Relevant For Cancer Immunotherapy ». Thesis, The University of Arizona, 2017. http://hdl.handle.net/10150/623490.
Texte intégralRecent advances in cancer immunology, highlighted by immune checkpoint inhibitors, have demonstrated that immunotherapy is a viable option in the oncologist’s armamentarium. Despite these advances, many patients are nonresponders. Preliminary studies have suggested that non-responders lack a de-novo anti-tumor antigen immune response that can be unmasked by checkpoint blockade; thus, strategies to induce anti-tumor immune responses are needed. We hypothesized that many tumor associated antigens (Ag) are readily susceptible to immune attack, but only in the context of identifying the tumor antigen epitopes that can reliably initiate an immune response, regardless of individual patient human leukocyte antigen (HLA) haplotype restrictions. We further hypothesized that epitope prediction strategies which seek to identify pan- or highly promiscuous-HLA binding epitopes would reduce the number of potential candidates and be more likely to accurately identify high-priority tumor Ag epitopes. Utilizing known HLA-serotype frequencies and setting a threshold of ninety percent of population coverage, regardless of race or ethnicity, twenty-nine different HLA-DRB1 haplotypes were chosen for antigen prediction utilizing the open source epitope prediction algorithm netMHCIIpan. Predictions were also performed for HLA-A serotypes utilizing the open source algorithm netMHCpan. Predicted epitopes were synthesized in the form of synthetic long peptides and tested in immune system sensitization assays involving unfractionated peripheral blood mononuclear cells (PBMC). Briefly, PBMC were subjected to a two-step culture, first synchronizing their exposure to the long peptides with aggressive surrogate activation of innate immunity, followed by IL-7-modulated T-cell hyperexpansion. Predictions resulted in identification of highly promiscuous-HLA binding epitopes. Unexpectedly, these epitopes clustered together forming high priority regions: unique “hot spots” with high densities of promiscuous HLA-binding epitopes from the widely expressed oncoproteins MUC1, HER2/neu and CMV-pp65 (p<0.0001, for predicted HLA-DRB1 binding affinities, compared to non-hot spot regions). Added synthetic long peptides (>20aa) derived from “hot spot” regions of MUC1, HER2/neu, and CMVpp65 reliably produced selective and sustained expansion of both CD4+ and CD8+ peptide-specific, interferon-γ (IFNγ)-producing Tcells when synchronized with step 2 exposure to exogenous IL-7 (p<0.0001 and p=0.0048, for CD4+ and CD8+ Ag-specific T-cells, respectively, compared to T-cells directed against peptides from non-hot spot regions). “Hot spot” peptide Ag-specific T-cells preferentially recognized endogenous tumor derived MUC1, either in MUC1 expressing tumor cell killing assays (p=0.038, compared to non-peptide Ag-specific T-cells) or as MUC1 tumor lysate when pulsed onto restimulatory PBMC (p=0.022 and 0.025, for CD4+ and CD8+ T-cells, respectively, compared to T-cells directed against peptides from non-hot spot regions). This mechanistically rational antigen selection sequence, effective even for unvaccinated donors, regardless of HLA-haplotype, enables rapid identification of tumor protein regions relevant for cancer immunology, including adoptive immunotherapy, vaccines, and even identification of tumor neo-antigens unique to each patient.
Yamazaki, Yuji. « Investigation on Chemical and Enzymatic Synthesis of Tumor Associated Carbohydrate Antigens Triggering Immune Responses ». Kyoto University, 2019. http://hdl.handle.net/2433/242472.
Texte intégralMalhi, S. K. « Molecular expression and immunotherapeutic potential of the novel tumour associated antigen T21 ». Thesis, Nottingham Trent University, 2013. http://irep.ntu.ac.uk/id/eprint/351/.
Texte intégralWong, Kah-Keng. « Validation of lymphoma-associated antigens identified using autoantibody profiling and protein arrays ». Thesis, University of Oxford, 2011. http://ora.ox.ac.uk/objects/uuid:51ac6bbe-2845-43cc-9b7a-cb92097155f1.
Texte intégralTrabbic, Kevin R. « Approaches to Increase the Immunogenicity of Carbohydrate Antigens Using PS A1 and Subsequent Immunotherapies ». University of Toledo / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1470330973.
Texte intégralNilsson, Stinabritt. « Synthesis of blood-group and tumour-associated oligosaccaharides and a bacterial polysaccharide fragment ». Lund : Organic Chemistry 2, Lund Institute of Technology, University of Lund, 1992. http://books.google.com/books?id=U-dqAAAAMAAJ.
Texte intégralFERNANDEZ, S. M. ALVAREZ. « SEROLOGICAL IMMUNE RESPONSE AGAINST ADAM10 IN COLORECTAL CANCER PATIENTS IS A FAVORABLE SIGNATURE ». Doctoral thesis, Università degli Studi di Milano, 2014. http://hdl.handle.net/2434/243933.
Texte intégralPlunkett, Timothy Andrew. « Studies of the murine and human immune response to the tumour-associated antigen MUC1 ». Thesis, King's College London (University of London), 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.402445.
Texte intégralTARASIUK, OLGA. « Phage display selection and development of monoclonal antibodies against Protein Disulfide Isomerase, a novel tumor associated antigen and potential target for cancer immunotherapy ». Doctoral thesis, Università del Piemonte Orientale, 2018. http://hdl.handle.net/11579/105204.
Texte intégralTrimpe, Kevin L. « Modulation of cell-cycle associated antigen expression by the B16 melanoma : multiparameter analysis using monoclonal antibodies and flow cytometry / ». The Ohio State University, 1985. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487264603217361.
Texte intégralKremling, Heidi [Verfasser], et Olivier [Akademischer Betreuer] Gires. « Expression and function of the tumor associated antigen EpCAM in early esophageal carcinoma / Heidi Kremling. Betreuer : Olivier Gires ». München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2014. http://d-nb.info/1071803522/34.
Texte intégralKawahara, Masahiro. « Identification of HLA class 1-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis ». Kyoto University, 2007. http://hdl.handle.net/2433/135730.
Texte intégralKleski, Kristopher A. « Progress of Entirely Carbohydrate Conjugates in Cancer Immunotherapeutics – Syntheses and Developments ». University of Toledo / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1586980386810219.
Texte intégralZou, Jun. « Characterization of peptides and phage that bind galectin-3 selected from bacteriophage display libraries a study of the role of galectin-3 in metastasis-associated cancer cell adhesion / ». Diss., Columbia, Mo. : University of Missouri-Columbia, 2005. http://hdl.handle.net/10355/4149.
Texte intégral"December 2005" The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Vita. Includes bibliographical references.
Writer, Michele. « Molecular analysis of the recognition of the tumour associated antigen CD55 by the mouse monoclonal antibody 791T/36 ». Thesis, University of Nottingham, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.342476.
Texte intégralBaxter, Katherine Elizabeth. « Developing an Oncolytic Prime-Boost Vaccine Targeting the Tumour Associated Antigen Mesothelin for the Treatment of Pancreatic Cancer ». Thesis, Université d'Ottawa / University of Ottawa, 2020. http://hdl.handle.net/10393/40024.
Texte intégralAbdulmajed, Hind Abdulrazak Yassin. « Identification of tumour associated antigens as potential targets for the immunotherapy of B-cell chronic lymphocytic leukaemia (B-CLL) ». Thesis, University of Leicester, 2008. http://hdl.handle.net/2381/9157.
Texte intégralDas, Krishna [Verfasser], et Stefan [Akademischer Betreuer] Eichmüller. « Generation of a transplantable murine tumor model expressing the human breast cancer associated tumor antigen NY-BR-1 in HLA-DRB1*0401-transgenic mice / Krishna Das ; Betreuer : Stefan Eichmüller ». Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1178009513/34.
Texte intégralDas, Krishna [Verfasser], et Stefan B. [Akademischer Betreuer] Eichmüller. « Generation of a transplantable murine tumor model expressing the human breast cancer associated tumor antigen NY-BR-1 in HLA-DRB1*0401-transgenic mice / Krishna Das ; Betreuer : Stefan Eichmüller ». Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1178009513/34.
Texte intégralBERNARD, DOMINIQUE. « Expression des antigenes hla-dr par le tissu mammaire dans les cancers du sein ». Clermont-Ferrand 2, 1986. http://www.theses.fr/1986CLF2E367.
Texte intégralAmarnath, Shoba Maria Prescilla. « Specific cytotoxic T lymphocyte immunity against hTERT in breast cancer and optimisation of dendritic cell maturation for presenting tumour associated antigens ». Thesis, University of Hull, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.411929.
Texte intégralPerini, Silvana. « Efeito da hipoxia intermitente em marcadores de progressão de melanoma em um modelo de apneia do sono em camundongos ». reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2013. http://hdl.handle.net/10183/72432.
Texte intégralStudy Objectives: Increased melanoma growth has been reported in mice exposed to intermittent hypoxia. Proteins that characterize tumor aggressiveness have not been investigated. The study aims to verify whether intermittent hypoxia mimicking sleep apnea affects markers of melanoma tumor progression. Design: Prospective controlled animal study. Settings: University hospital. Participants: Twelve C57bl/6 mice. Interventions: Mice were exposed to intermittent or sham hypoxia. During 8 hours per day, the hypoxia group was submitted to a total of 480 cycles of 30 seconds of progressive hypoxia to a nadir FIO2 of 8±1%, followed by 30 seconds of normoxia. One million B16F10 melanoma cells were injected subcutaneously. On the 14th day, after euthanasia, tumors were removed, fixed and stained. Measurements and Results: Immunohistochemistry staining for Ki-67, PCNA, S100-B, HMB-45, Melan-A, TGFβ, Caspase-1 and HIF-1α was quantified by two observers using digital capture and processing in three slides from each animal for each marker. The size and weight of the tumors were similar in hypoxia and simulated experiments. Median [25-75 quartiles] percentage of positive area stained for Ki-67 was 23% [15-28] in the hypoxia group and 0.3% [0.2-1.1] the control group (P=0.02); for PCNA, the percentages were 31% [25-38] e 7% [5-18], respectively (P=0.009). The differences between the groups for the remaining markers were not significant. Conclusions: Markers of ribosomal RNA transcription and of DNA synthesis are more expressed in tumors of mice exposed to intermittent hypoxia than of controls, indicating that sleep apnea can lead to greater tumor aggressiveness.
Gardyan, Adriane [Verfasser], et Stefan [Akademischer Betreuer] Eichmüller. « Identification of CD4+ T cell epitopes specific for the breast cancer associated tumor antigen NY-BR-1 using HLA-transgenic mice / Adriane Gardyan ; Betreuer : Stefan Eichmüller ». Heidelberg : Universitätsbibliothek Heidelberg, 2015. http://d-nb.info/1180499123/34.
Texte intégralBonney, Laura Catherine. « Study into the role of lactadherin as a tumour associated antigen and angiogenesis factor : investigating HuMc3 (Angiolix®) as a therapeutic antibody for cancer ». Thesis, Imperial College London, 2011. http://hdl.handle.net/10044/1/6398.
Texte intégralCescato, Valter Angelo Sperling. « Expressão dos genes relacionados à apoptose, Bcl-2, bax, e caspase-3 nos adenomas hipofisários clinicamente não funcionantes e seu potencial como marcador do comportamento tumoral ». Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5138/tde-10052010-151708/.
Texte intégralPituitary adenomas are benign, slow-growing tumors that arise in the sella turcica and account for 10% to 15% of all intracranial tumors. Non-functioning pituitary adenomas (NFPA) account for around one third of all pituitary adenomas. NFPA do not clinically present as hormonal syndromes and are generally diagnosed as macroadenomas due to marked neurological and ophthalmologic symptoms and invasion of surrounding structures, beside hypopituitarism. Surgery is the gold standard to treat these tumors. It effectively relieves compressive symptoms but cure is uncommon. Despite benign in nature, NFPA usually show aggressive behavior. There are no hormonal markers and the follow-up usually is made only by magnetic resonance imaging. Apoptosis-related genes, Bcl-2, Bax, and caspase-3, were here studied in NFPA to assess their role as potential markers of tumor behavior. Out of 119 patients with pituitary adenomas treated by surgery, 30 patients (17 men, 13 women, median age 54.5 years old) harboring NFPA who underwent surgery in the Department of Functional Neurosurgery at Hospital das Clínicas Psychiatric Institute, University of S. Paulo Medical School, from August 2008 to July 2009, were studied. Information on gender, age, pituitary function, symptoms and their length was collected. Tumor dimensions were measured using magnetic resonance imaging of the sella turcica. The tumor volume was calculated by the following equation: anterior-posterior diameter x cranial-caudal diameter x lateral-lateral diameter x 0.5. Intra-operative information such as tumor invasion and consistence was recorded. Histological examination by hematoxylin-eosin staining and immunohistochemistry analysis of pituitary hormones, Ki-67, p53, and Bcl-2 were performed. The molecular analysis of Bcl-2, Bax, and caspase-3 genes was performed by real-time polymerase chain reaction (RT-PCR) in all tumor specimens collected during surgery and compared to a poll of normal pituitary gland. All patients had macroadenomas diagnosed due to visual loss (87%), headache (53%) and other neurological symptoms (17%) and one case was incidentally found. Hormonal deficits were seen in 92% of 26 cases; more than two axes were involved in half of these patients. There was found good correlation between tumor volume, largest diameter and the sum of the 3 diameters, and tumor volume was used to assess the correlations with other parameters. The median volume was 11.6 cm3. Giant tumors (4 cm) were diagnosed in 40% of the patients. Soft tumors and tumor invasion were observed in 87% and 67% of cases, respectively. A transsphenoidal approach was used in all patients, except one who had pterional craniotomy. Five patients presented post-operative complications: three had CSF leakage, two meningitis and two died. The histological examination confirmed pituitary adenoma in all cases, 18 of them were null cell and 12 showed a positive immunohistochemistry analysis for one or more hormones, mainly TSH. Immunohistochemistry analysis results for p-53 was negative in all cases; for Ki-67 was negative in 11, positive in less than 3% of the cells in 15 and positive in more than 3% of the cells in 4 cases; and for Bcl-2 was positive only in three patients. Bcl-2, Bax and caspase-3 molecular analysis revealed very low expression compared to normal pituitary values. There was found a positive correlation between these three genes but no correlation between them and age, tumor volume or invasion. The Bcl-2, Bax, and caspase-3 gene analysis by RT-PCR in NFPA did not evidence their potential as markers of tumor behavior
Wu, Xianglei. « Évaluation concomitante des signatures fonctionnelles des réponses lymphocytaires T spécifiques des Antigènes Associés aux Tumeurs et des Cellules Tumorales Circulantes : Impact sur le pronostic des patients atteints de carcinome épidermoïde des voies aéro-digestives supérieures ». Thesis, Université de Lorraine, 2017. http://www.theses.fr/2017LORR0037/document.
Texte intégralWe have evaluated herein two important parameters in the immunomonitoring of cancer patients: circulating tumor cells (CTC) as an indicator of “tumoral antigenic load” and tumor-associated antigens (TAA) specific T-cells. We firstly evaluated the diagnostic and prognostic value of CTC in Head and Neck Squamous Cell Carcinoma (HNSCC) by a systematic review and meta-analysis. We came to the conclusion that current evidence identifies the CTC detection test as an extremely specific but low sensitive test in HNSCC. In addition, the presence of CTC indicates a worse disease-free disease (DFS). Also, we report for the first time a rare case of extremely high enumeration of circulating tumor cells detected in a patient with squamous cell carcinoma of the oral cavity using the CellSearch® system. The absolute number of CTC could therefore predict a particular phase of cancer development as well as a poor survival, potentially contributing to personalized health. In addition, we describe an adaptation of the CellSearch® method that we have developed for detecting tumor cells in the cerebrospinal fluid of patients with carcinomatous meningitis. This new approach reaches a significantly improved sensitivity compared to conventional cytology. CellSearch® technology, applied to limited sample volumes and allowing an increased pre-analytical time, may be of great interest in the diagnosis of leptomeningeal metastases in patients with epithelial cancer. By a concomitant evaluation of CTC and TAA-specific lymphocyte responses in 24 HNSCC patients, we describe that CTC could be an independent indicator of immunogenic tumor burden. The absence of CTC, the presence of TAA-specific T-cells, or the combination of these, were all parameters showing a trend for a better overall survival or DFS. The amplitude and functional signatures of TAA-specific T-lymphocytes in patients with HNSCC were associated with the presence of CTC. These results suggest that a concomitant evaluation of these two parameters may be more pertinent for prognosis assessment as well as for treatment impact, especially in “checkpoint-inhibitors” new immunotherapies
Mustafa, Mohammad Zahid. « Autoantibody signatures defined by serological proteome analysis in sera of patients with cholangiocarcinoma ». Phd thesis, Université Paris Sud - Paris XI, 2014. http://tel.archives-ouvertes.fr/tel-01058149.
Texte intégralAzria, David. « Association du facteur de nécrose tumorale (TNFα) et de la radiothérapie dans les cancers digestifs exprimant l'antigène carcinoembryonnaire (ACE) : intérêts d'un anticorps bispécifique anti-ACE/anti-TNFα ». Montpellier 1, 2004. http://www.theses.fr/2004MON1T005.
Texte intégral